PMID- 33008300
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20210514
IS  - 1471-230X (Electronic)
IS  - 1471-230X (Linking)
VI  - 20
IP  - 1
DP  - 2020 Oct 2
TI  - Peritumoral ductular reaction can be a prognostic factor for intrahepatic 
      cholangiocarcinoma.
PG  - 322
LID - 10.1186/s12876-020-01471-0 [doi]
LID - 322
AB  - BACKGROUND: Peritumoral ductular reaction (DR) was reported to be related to the 
      prognosis of combined hepatocellular-cholangiocarcinoma and hepatocellular 
      carcinoma. Non-mucin-producing intrahepatic cholangiocarcinoma (ICC) which may be 
      derived from small bile duct cells or liver progenitor cells (LPCs) was known to 
      us. However, whether peritumoral DR is also related to non-mucin-producing ICCs 
      remains to be investigated. METHODS: Forty-seven patients with 
      non-mucin-producing ICC were eventually included in the study and 
      clinicopathological variables were collected. Immunohistochemical analysis and 
      immunofluorescence staining for cytokeratin 19, proliferating cell nuclear 
      antigen, and alpha-smooth muscle actin were performed in tumor and peritumor liver 
      tissues. RESULTS: A significant correlation existed between peritumoral DR and 
      local inflammation and fibrosis. (r = 0.357, 95% CI, 0.037-0.557; P = 0.008 and 
      r = 0.742, 95% CI, 0.580-0.849; P < 0.001, respectively). Patients with obvious 
      peritumoral DR had high recurrence rate (81.8% vs 56.0%, P = 0.058) and poor 
      overall and disease-free survival time (P = 0.01 and P = 0.03, respectively) 
      comparing with mild peritumoral DR. Compared with the mild peritumoral DR group, 
      the proliferation activity of LPCs/ cholangiocytes was higher in obvious 
      peritumoral DR, which, however, was not statistically significant. (0.43 +/- 0.29 
      vs 0.28 +/- 0.31, P = 0.172). Furthermore, the correlation analysis showed that the 
      DR grade was positively related to the portal/septalalpha-SMA level (r = 0.359, 
      P = 0.001). CONCLUSIONS: Peritumoral DR was associated with local inflammation 
      and fibrosis. Patients with non-mucin-producing ICC having obvious peritumoral DR 
      had a poor prognosis. Peritumoral DR could be a prognostic factor for ICC. 
      However, the mechanism should be further investigated.
FAU - Shen, Zhenyang
AU  - Shen Z
AD  - Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Xiao, Jingbo
AU  - Xiao J
AD  - Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Wang, Junjun
AU  - Wang J
AD  - Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Lu, Lungen
AU  - Lu L
AD  - Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Wan, Xinjian
AU  - Wan X
AD  - Department of Gastroenterology, Shanghai Sixth People's Hospital, Shanghai Jiao 
      Tong University School of Medicine, Shanghai, China.
FAU - Cai, Xiaobo
AU  - Cai X
AD  - Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China. caixiaobo1979@hotmail.com.
LA  - eng
GR  - 2018ZX09201016/National Science and Technology Major Special Project for New Drug 
      Development/
PT  - Journal Article
DEP - 20201002
PL  - England
TA  - BMC Gastroenterol
JT  - BMC gastroenterology
JID - 100968547
SB  - IM
MH  - *Bile Duct Neoplasms
MH  - Bile Ducts, Intrahepatic
MH  - *Cholangiocarcinoma
MH  - Humans
MH  - *Liver Neoplasms
MH  - Neoplasm Recurrence, Local
MH  - Prognosis
PMC - PMC7532600
OTO - NOTNLM
OT  - Ductular reaction
OT  - Intrahepatic cholangiocarcinoma
OT  - Peritumoral
OT  - Prognosis
COIS- The authors declare that they have no competing interests.
EDAT- 2020/10/04 06:00
MHDA- 2021/05/15 06:00
PMCR- 2020/10/02
CRDT- 2020/10/03 05:20
PHST- 2020/04/30 00:00 [received]
PHST- 2020/09/25 00:00 [accepted]
PHST- 2020/10/03 05:20 [entrez]
PHST- 2020/10/04 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/10/02 00:00 [pmc-release]
AID - 10.1186/s12876-020-01471-0 [pii]
AID - 1471 [pii]
AID - 10.1186/s12876-020-01471-0 [doi]
PST - epublish
SO  - BMC Gastroenterol. 2020 Oct 2;20(1):322. doi: 10.1186/s12876-020-01471-0.